MIRAGE Study: Clinical Outcomes of the Mamba Sirolimus-Eluting PTCA Balloon
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.
Also called NCT07326735
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 360 participants
- Sponsor
- Frisch Medical Device Private Limited
- Registry
-
NCT07326735
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Myanmar (Burma), Malaysia
- Registry status
- Completed
Technical summary
Registry record NCT07326735. Allocation not applicable; no masking; primary purpose treatment. Start 2023-01-11 (actual); primary completion 2024-01-22 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- MIRAGE Study: Clinical Outcomes of the Mamba Sirolimus-Eluting PTCA Balloon
- Condition
- Coronary Artery Disease (CAD (coronary artery disease)) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
- Intervention (Device)
- Mamba Sirolimus-Eluting PTCA Balloon
- Intervention (Device)
- Percutaneous Coronary Angioplasty with Sirolimus-Coated Balloon
- Lead sponsor
- Frisch Medical Device Private Limited
Record details
- Record id
cardio:ct-nct07326735- Content hash
bd6bff2c371c465177a3e9543a3fbdf23d89aec382d9a94f523dbc472fffa1a8